A diagnosis of pediatric multiple sclerosis is associated with a T1 hypointense lesion and a T2 periventricular lesion on baseline MRI.
Pediatric demyelinating disease specialists have proposed several magnetic resonance imaging (MRI) criteria for early differentiation of multiple sclerosis (MS) from a monophasic acquired demyelinating syndrome (ADS). For this multicenter, longitudinal, prospective study, researchers recruited 284 patients with ADS who were younger than 16 years. MRI was performed by a standardized protocol at baseline, 3, 6, and 12 months; additional MRIs were done either annually or when clinically indicated. MS was diagnosed at the time of a second episode of demyelination — defined as a new clinical event or new MRI lesions. The researchers used a detailed, 14-parameter scoring system to characterize each MRI scan.
During a mean follow-up of 3.9 years, 2…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)